Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 568

Results For "EU"

5984 News Found

Covid-19 infected individuals need only one dose of Covaxin: ICMR study
News | August 28, 2021

Covid-19 infected individuals need only one dose of Covaxin: ICMR study

Blood samples were collected from 114 healthcare workers who received Covaxin in Chennai from February to May 2021


U.S. FDA approves drug-free VNS system for stroke
Drug Approval | August 28, 2021

U.S. FDA approves drug-free VNS system for stroke

When used alongside rehabilitative exercise, this device may offer benefit to those who have lost function in their upper limbs due to ischemic stroke


Japan approves AstraZeneca’s Forxiga for chronic kidney disease
Drug Approval | August 28, 2021

Japan approves AstraZeneca’s Forxiga for chronic kidney disease

Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options


SEC recommends Phase I clinical trials for Reliance’s Covid-19 vaccine candidate
News | August 27, 2021

SEC recommends Phase I clinical trials for Reliance’s Covid-19 vaccine candidate

The company has to approach the DCGI for approval to commence the trials


Indoco’s AnaCipher receives UK-MHRA accreditation
Drug Approval | August 27, 2021

Indoco’s AnaCipher receives UK-MHRA accreditation

The clinical research organisation located in Hyderabad is a USFDA inspected facility


Pharma continues to attract PE investments: Care Ratings
News | August 27, 2021

Pharma continues to attract PE investments: Care Ratings

In H1FY21, it attracted PE deals worth US $ 1.6 billion compared to US $ 3 billion in CY2020


Pfizer and BioNTech initiate rolling submission for Comirnaty booster dose
Drug Approval | August 26, 2021

Pfizer and BioNTech initiate rolling submission for Comirnaty booster dose

The submission to the US FDA has been initiated and they intend to file these data with the European Medicines Agency and other regulatory bodies in the coming weeks


Johnson & Johnson booster dose indicate impressive results
Drug Approval | August 26, 2021

Johnson & Johnson booster dose indicate impressive results

New interim data from these studies demonstrate that a booster dose of the Johnson & Johnson Covid-19 vaccine generated a rapid and robust increase in spike-binding antibodies, nine-fold higher than 28 days after the primary single-dose vaccination.


Adjuvance announce clinical results of its next-gen saponin adjuvant
Biotech | August 26, 2021

Adjuvance announce clinical results of its next-gen saponin adjuvant

First results demonstrate favourable tolerability of TQL-1055 at all dose levels


Wockhardt and Jemincare partner for novel respiratory antibiotic Nafithromycin
Drug Approval | August 26, 2021

Wockhardt and Jemincare partner for novel respiratory antibiotic Nafithromycin

The company to receive upfront and milestone payments, in addition to royalties